Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone
Authors
Keywords
-
Journal
LEUKEMIA
Volume 30, Issue 4, Pages 776-781
Publisher
Springer Nature
Online
2015-11-25
DOI
10.1038/leu.2015.326
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
- (2015) Nicole C.C. Them et al. AMERICAN JOURNAL OF HEMATOLOGY
- Ropeginterferon alfa-2b, a novel IFN -2b, induces high response rates with low toxicity in patients with polycythemia vera
- (2015) H. Gisslinger et al. BLOOD
- Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
- (2015) A Burchert et al. LEUKEMIA
- Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response
- (2015) Marco Pizzi et al. MODERN PATHOLOGY
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
- (2015) Gabriela M. Baerlocher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapy for myeloproliferative neoplasms: when, which agent, and how?
- (2014) H. L. Geyer et al. BLOOD
- Expansion of circulating CD56brightnatural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α
- (2014) Caroline H. Riley et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons
- (2014) Eric M. Pietras et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms
- (2014) Hans C Hasselbalch Expert Review of Hematology
- An Immune Dysregulation in MPN
- (2014) Giovanni Barosi Current Hematologic Malignancy Reports
- Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
- (2013) G. Barosi et al. BLOOD
- Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon- in a murine model of polycythemia vera
- (2013) A. Mullally et al. BLOOD
- JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN
- (2013) S. Hasan et al. BLOOD
- Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
- (2013) H. Gisslinger et al. BLOOD
- Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon -2a
- (2013) A. Quintas-Cardama et al. BLOOD
- Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups
- (2013) Jean-Christophe Ianotto et al. BRITISH JOURNAL OF HAEMATOLOGY
- Use of the 46/1 haplotype to model JAK2 V617F clonal architecture in PV patients: clonal evolution and impact of IFNα treatment
- (2013) S Hasan et al. LEUKEMIA
- Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
- (2013) J V Jovanovic et al. LEUKEMIA
- Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha
- (2013) Thomas Stauffer Larsen et al. LEUKEMIA RESEARCH
- Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
- (2013) Richard T Silver et al. Expert Review of Hematology
- Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera
- (2012) A. Mullally et al. BLOOD
- Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting
- (2012) Evgeny Klyuchnikov et al. BRITISH JOURNAL OF HAEMATOLOGY
- Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives
- (2012) Hans Carl Hasselbalch et al. CURRENT DRUG TARGETS
- Biological therapy and the immune system in patients with chronic myeloid leukemia
- (2012) Peter Rohon INTERNATIONAL JOURNAL OF HEMATOLOGY
- Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
- (2012) Hans Carl Hasselbalch LEUKEMIA RESEARCH
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
- (2011) A. Alvarez-Larran et al. BLOOD
- Recombinant interferon- may retard progression of early primary myelofibrosis: a preliminary report
- (2011) R. T. Silver et al. BLOOD
- The renaissance of interferon therapy for the treatment of myeloid malignancies
- (2011) J.-J. Kiladjian et al. BLOOD
- Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-
- (2011) C. H. Riley et al. BLOOD
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
- (2011) Jean-Jacques Kiladjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Interferon-α Abrogates Tolerance Induction by Human Tolerogenic Dendritic Cells
- (2011) Nicole Bacher et al. PLoS One
- Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile
- (2011) Anna Kreutzman et al. PLoS One
- Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway
- (2010) Min Lu et al. EXPERIMENTAL HEMATOLOGY
- Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
- (2010) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2 V617F clones without affecting TET2 mutant cells
- (2010) J-J Kiladjian et al. LEUKEMIA
- Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission
- (2009) Thomas Stauffer Larsen et al. Hematology
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- IFNα activates dormant haematopoietic stem cells in vivo
- (2009) Marieke A. G. Essers et al. NATURE
- The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity
- (2008) C. James et al. BLOOD
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
- Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
- (2008) J-J Kiladjian et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More